Nourish Body, Mind, & Soul: Introducing Mantra™ from BlenderBottle
Lehi, Utah (November 2018) – BlenderBottle, the brand that revolutionized the portable protein mixer market, introduces their latest innovation in customer-focused engineering and design: the BlenderBottle® Mantra™ glass protein shaker. The strikingly modern bottle debuts today at BlenderBottle.com.
The BlenderBottle Mantra shaker was inspired by the calming, clarity-inspiring experience of drinking directly from glass. “We’ve found that a number of our customers strongly prefer drinking from glass. But most glass bottles on the market utilize plastic or other materials in the drinking spout. We sought to solve this dilemma for glass-bottle purists. Our all-new ClearSip™ spout is the result of this consumer-focused design,” says Michael Sorensen, Marketing Director at BlenderBottle.
Mantra’s sleek and simple aesthetic belie surprisingly sophisticated function. The bottle’s unique, center-mounted ClearSip Spout creates a smooth, all-glass drinking surface. A second, wider opening allows for thorough cleaning of the all-glass bottle; plus it easily accommodates supplement scoops or ice. The glass bottle is nestled between a silicone cap and boot for enhanced grip.
Whether you’re sipping water during yoga practice or mixing a recovery shake after a round of heavy reps, the Mantra protein shaker provides plenty of additional premium features. The secure, twist-on cap and screw-on lid create a leak-proof seal—backed by BlenderBottle’s Leak Proof Guarantee. The detachable carry loop allows you to easily secure your keyring to the bottle, or latch the bottle to your gym bag. The patented mixing system uses the BlenderBall® wire whisk—found only in BlenderBottle brand shakers—to mix protein and nutrition shakes with ease. The Mantra is stain and odor resistant, made of BPA- and phthalate-free materials, and top-rack dishwasher safe.
The BlenderBottle Mantra protein shaker is offered in clear glass with five accent color options: Black, Plum, Spruce, Rose, and Pebble. The 20-ounce capacity bottle retails for $19.99 and is available now at blenderbottle.com.
About BlenderBottle
Founded in 2000, the BlenderBottle Company is a privately held manufacturer of premium and innovative products that help simplify everyday life. The company’s patented and best-selling products have been hailed by Good Morning America, Reader’s Digest, Self, the Today Show, Men’s Fitness, and others as some of the “hottest new products” on the market.
BlenderBottle® products are available in over 90,000 retail locations worldwide, and in over 70,000 retail locations in the U.S. alone, including GNC, Vitamin Shoppe, Vitamin World, Bed Bath & Beyond, Walmart, Target, Rite Aid, Whole Foods, Amazon.com, and online at blenderbottle.com. The BlenderBottle Company is located in Lehi, Utah and markets and sells its products to retailers and resellers worldwide. All BlenderBottle® products are backed by a Customer Satisfaction Guarantee. For additional information, visit blenderbottle.com.
WINTER HEALTH MYTHS BUSTED!
https://tourocom.touro.edu/academics/faculty/harlem/niket-sonpal.php
There are endless winter health myths that we have heard from well intentioned grandparents and parents. They have become so ingrained in us that we take them as cold hard facts. Many of these myths have no more basis in reality than Santa Claus. Of course, everyone wants to stay as healthy as possible during the frosty months. In order to do so sensibly, we turned to Board Certified NYC internist and gastroenterologist Dr. Niket Sonpal.
Myth: Allergies go away in the winter
Allergies might be the real source behind your stuffy nose and scratchy throat this season. According to the Asthma and Allergy Foundation of America, one in five people suffer from indoor/outdoor allergies, and the indoor variety can actually be worse in the winter. Dr. Sonpal cautions that, “If your symptoms last longer than 10 days or ease up after taking an antihistamine, it might be time to visit an allergist.”
Myth: I wash my hands all the time with hand sanitizer, so I should be fine.
Hand sanitizer will kill most viruses, but not all. You must make sure you use the right amount of hand sanitizer and let it dry completely. Dr. Sonpal points out that,” Some viruses, like norovirus, which causes vomiting, is not killed by hand sanitizer. Soap and water are best to get rid of all bacteria and viruses, but the hand sanitizer is better than nothing at all.”
Myth: It’s cold out, I don’t need sunscreen.
The sun’s rays are just as strong in the winter months as they are in the other seasons. Snow and ice can reflect even more sunlight, up to twice as much. Grab the SPF 30 and put it on, regardless of the temperature. Don’t forget those sunglasses to keep your eyes safe as well.
I’ll just drink some alcohol to keep myself warm.
Although it may feel like drinking alcohol is making you warmer, it does not. Dr. Sonpal says that, “when you drink, the blood vessels dilate or get bigger, and blood flows to your skin and away from your internal organs. So, it may feel like you are getting warmer, but you are not.”
Myth: The Flu Shot Gives You the Flu
According to a new survey from the National Foundation for Infectious Diseases and Rite Aide, 44 percent of American women view the flu as a serious threat to their health. Yet nearly half (49 percent) do not intend to get a flu shot this year because they believe the vaccine can give them the flu. The U.S. Centers for Disease Control and Prevention recommends the flu shot for anyone older than 6 months of age. Dr. Sonpal stresses that, “The shot does not contain a live virus, making catching the flu from it impossible.”
Winter weather makes you store fat and gain weight
Our bodies do not go into some kind of winter hibernation mode, stockpiling every ounce of fat to use for the lean times. It seems logical, like a throwback to our days living in caves foraging for food, but in reality, any weight gain comes from our winter habits. Dr. Sonpal points out that, “we tend to exercise less in winter. We eat more hearty meals and comfort foods, including more sugary snacks and desserts (especially around the holidays).”
Myth: You Lose Most Heat Through Your Head
The saying goes “we lose 90 percent of our body heat through our heads.” But a 2006 study found that the head accounts for about 7 percent of the body's surface area, and that heat loss in the region is fairly proportional, according to LiveScience. "Your head is another extremity, and it's susceptible to cold, so you should wear a hat, but it doesn't lose any more heat than another part of your body," says Dr. Sonpal.
Myth: Chicken Soup Will Cure Colds
Many cultures teach us to drink warm liquids like tea, hot apple cider, and soups when we’re dealing with colds. It’s true that something like chicken soup may help soothe and ease congestion, but much like vitamin C, hot soup won’t do immediate wonders.
Myth: Being Cold Gives You a Cold
No matter what your grandma might have told you, spending too much time in the cold air doesn’t make you sick. One study found that healthy men who spent several hours in temperatures just above freezing had an increase in healthy, virus-fighting activity in their immune systems. In fact, you’re more likely to get sick indoors, where germs are easily passed.
Myth: Feed a cold, starve a fever
Dr. Sonpal says that, “This is another myth that comes from a time when people didn't understand the science of body chemistry. The thought was that if you had a cold, food would warm you up. Conversely, if you had a high fever, not eating would cool you down. This is just patently bad medical advice. In both cases, good nutrition gives your body the fuel it needs to fight infections and recover from an illness. When you have a fever, your body is burning energy at a rapid rate, and that needs to be replenished. So, by all means feed your cold; but also feed your fever, or any other illness. Even if you have stomach issues, find a way to take in lost fluids and electrolytes.”
About Dr. Niket Sonpal:
Dr. Niket Sonpal is a native of Long Island NY and a graduate of Medical University of Silesia – Hope Medical Institute in Poland. After completing his residency in Internal Medicine at Lenox Hill Hospital, he was selected to be the 2013‐2014 Chief Resident at Lenox Hill Hospital–Northshore LIJ Health System. He is an Adjunct Assistant Professor at Touro College of Osteopathic Medicine and Clinical instructor at Kingsbrook Jewish Medical Center, Brooklyn. Dr. Sonpal has completedhis Fellowship in gastroenterology & hepatology at Lenox Hill Hospital and will continue his work in the field of medical student and resident test preparation. He now serves as the associate program director for the Internal Medicine Residency Program at Brookldale University medical center.
He is the co‐author for the best-selling Master the Boards: USMLE Step 2 CK, Master the Boards Step 3, And Master the Boards: Internal Medicine. He is also the Chief Operating Officer for Medquest Test Prep, Director of Medical Education for Picmonic Test Prep, and a recognized expert on medical test prep.
Integrated Cannabis Company, Inc. Signs Definitive Agreement With Empower Clinics, Inc. and Receives Purchase Order
VANCOUVER, Nov. 7, 2018 /CNW/ - Integrated Cannabis Company, Inc. (CSE: ICAN) (OTCQB: ICNAF) ("Integrated Cannabis"), is pleased to announce the completion of a Definitive Agreement ("the Agreement") to distribute X-SPRAYS™ products throughout the clinics and doctors' offices of Empower Clinics Inc. (CSE: EPW; FRA: 8EC) ("Empower"), a leading owner and operator of medical cannabis and wellness clinics in the United States (US).
Integrated Cannabis has also received its initial purchase order from Empower for a selection of X-SPRAYS™ products. Empower has more than 25,000 patients under care across 15 locations with medical cannabis treatments in Oregon, Washington and Illinois. The patient base in Oregon represents approximately one-third of the state's total medical card issuance. In addition, Empower has an historical patient database of which exceeds 120,000 in the three States.
"This milestone marks another significant move for distribution of X-SPRAYS™ with its' first shipment to the Chicago market. We are excited to align with Empower and the City of Chicago and have our products available for people visiting their clinics in search of relief with issues like opioid addiction, pain, anxiety, sleep issues and people seeking overall well-being," said Mr. John Knapp, CEO of Integrated Cannabis.
"We love the X-SPRAYS™ products and look forward to expanding our suite of offerings through these innovative CBD sprays. X-SPRAYS™ state of the art formulations and unique metered dosage combine to consistently deliver a high quality product through our nationwide network of clinics," said Mr. Craig Snyder, CEO of Empower.
On September 12, Empower announced the opening of its flagship Chicago clinic. In Illinois, the company seeks to expand its operations and achieve a leadership position as it executes on parallel national clinic and product strategies. There is currently an opioid epidemic in the United States and the company's announced Chicago facility closely followed the endorsement by Illinois Governor Bruce Rauner of medical cannabis as a frontline treatment and alternative for patients with a new statewide measure he signed into law on Aug 28.
About Integrated Cannabis Company
Integrated Cannabis Company, Inc. is comprised of dedicated scientists and product engineers who are passionate about health and creating health and lifestyle products utilizing advanced delivery systems and formulations. For more information, please visit the company's website at: http://www.x-sprays.com .
ABOUT EMPOWER
Empower is a leading owner and operator of medical cannabis and wellness clinics, as well as a developer of medical products in the US, focused on enabling individuals to improve and protect their health. The company provides treatment solutions through its physician-staffed clinics that are focused on education, data, and efficacy. Empower is a recognized leader and the first choice for patients seeking quality experience and improved health.
ON BEHALF OF THE BOARD
"John Knapp"
Chief Executive Officer
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
SOURCE Integrated Cannabis Company, Inc.
Loss Is A Four-Letter Word: Provides The Tools To Help Anyone Who's Lost A Spouse Find Their Own Healing Journey Forward
"Carole Brody Fleet is forthright in dealing with many of the difficult issues surrounding widowhood, demonstrating that you do not have to live in your past. It's not an either-or situation. She teaches the important lesson that you can incorporate your previous life into a new life.”
— Jane Brody, personal health columnist, The New York Times
Deerfield Beach, FL, November 6, 2018 — No widow or widower look exactly the same. No widowhood looks exactly the same. Therefore, no healing journey or timeline is an identical experience. The word "loss” contains only four letters, but its size belies the amount of fear it produces at even its mere mention. Even more terrifying and enormous is the reality of loss–specifically, the loss of a spouse.
Widowhood has the capacity to keep those affected from moving forward into a new and fulfilling life. The loss of a spouse is frightening. The call for relatable and actionable direction and advice remains a very real need for the widowed community, and that is just what Loss is a Four-Letter Word offers. Award-winning author Carole Brody Fleet personally experienced the pain and grief as a young widow and mother; leaving her and her 9-year-old daughter alone. Loss is a Four-Letter Word shows readers a way out, a way to move forward– not "get over”–their most profound loss in positive ways. Fleet combines no-nonsense, direct advice with specific, boot-camp style "assignments” that are framed with compassion and humor to help them through a most challenging life-journey.
A short sample of the Bereavement Boot Camp Lessons:
• Lesson One: I'm Still Here
• Lesson Two: "My Healing Journey Is Mine”
• Lesson Three: Stop Putting Off Proactivity
• Lesson Four: "I Turn to… Who?”
• Lesson Five: Put Your Tits on Your Back
• Lesson Six: Get Up, Get Moving… Get Out!
• Lesson Seven: It's Your Turn
• Lesson Eight: Past, Present, and Future: You Can Have All Three
Loss is a Four-Letter Word gives readers help without reproach, education without lecture, and support without judgment, condition, or negative opinion. All of which provides a necessary light during such devastating times. Fleet tells them, "Because while our spouses may have departed this earth, we are still here. And we matter too.”
About the Author:
Carole Brody Fleet is the award-winning author of When Bad Things Happen to Good Women, Happily EVEN After, and Widows Wear Stilettos. Widely recognized as America's go-to expert on life adversity and grief recovery, Ms. Fleet is also a three-time contributor to the iconic Chicken Soup for the Soul book series, as well as a regular contributor to The Huffington Post and to ThirdAge.com. Ms. Fleet is also a popular motivational speaker and with her inimitable message of "What Now and What Next?” Ms. Fleet offers practical, emotional, and even humorous guidance to the millions who have experienced any kind of loss or challenge in their lives.
Loss Is A Four-Letter Word: A Bereavement Boot Camp for the Widowed
By Carole Brody Fleet
ISBN: 9780757321214
September 2018
$15.95
Available wherever books are sold or to order directly from the publisher,
Reviews:
Karen Noé, author, We Consciousness: 33 Profound Truths for Inner and Outer Peace and Your Life After Their Death: A Medium's Guide to Healing After a Loss: "Carole Brody Fleet has done it again! In Loss is a Four Letter Word, she offers practical, straightforward advice on how to move forward on a positive path after losing a loved one. I've had Carole as a guest on the "Angel Quest” radio show a number of times because of how much she has benefited my listeners with her knowledge. If it sounds like I am impressed with her, it's because I am. I love this book, and I love Carole!”
Lisa Lockwood, crime analyst, author, police and military veteran: "What I love and appreciate is Carole Brody Fleet's firsthand knowledge and approach on the most taboo topic in society. Having gone through personal loss, I always learn something about how to approach the topic with empathy and how to permit others to comfort me in the worst of times.”
Stacey Gualandi, Emmy award-winning journalist: "Carole Brody Fleet has faced painful challenges and loss with courage and resilience. Through her own personal healing, we can all learn from and be inspired by her. I have a four-letter word for Carole: HERO.”
Kristin Higson-Hughes, Senior Features Editor, Women's World Magazine: "Just as there is no timetable to grief, there certainly is no checklist on how to recover strength and joy after suffering a loss. Here you will find authentic, candid, trustworthy, and--perhaps most pertinent of all--pragmatic advice promising that although the landscape of life may forever be changed, the future can still hold purpose, beauty, and magic. With a signature style all her own, Carole Brody Fleet "trains" you to find yourself again (hint: there's no wrong path, but some are healthier for your soul!). Together, you will navigate everything from social media to financial matters to the possibility of finding love again. Sure, it can feel impossible to do, and even more so to find answers, but sign up, dear recruit, and discover this book's wit and wisdom, and its author's enormous-as-the-universe heart!"
Kim Iversen, nationally syndicated radio show host: "Carole is an angel, not just an expert. Many of us have no clue what to say to a loved one going through tremendous loss. We sit by and watch helplessly as they struggle with their 'new normal'. Carole's book is a must read; not just for widows, but for those of us who love a widow as well. As a relationship radio talk show host, I have always had words to comfort and guide someone through every type of heartache-----every heartache except the death of a spouse. This type of loss leaves many of us speechless. Finally, someone who knows what to say when the rest of us do not."
Survey Reveals Canadians Largely Unaware of Threat of Antimicrobial Resistance
MISSISSAUGA, ON, Nov. 6, 2018 /CNW/ - In acknowledgement of World Antibiotic Awareness Week, Nov. 12-18, a new survey examining Canadians' understanding of antimicrobial resistance (AMR) reveals that many are unfamiliar with and unconcerned about the threat of drug resistance.1,2
Drug-resistant infections are predicted to cause more deaths by 2050 than cancer and diabetes today, and without serious collective action, the spread of AMR could lead to an era in which common injuries and infections become lethal.3,4 With greater education on the topic, Canadians can become better equipped to take an active role in advocating for action against this threat.
The survey revealed:
- Only 29 per cent of Canadians surveyed consider themselves "somewhat" or "very" knowledgeable about AMR.2
- When asked about their personal overall health and well-being, Canadians ranked AMR among conditions that were of least concern.2
- Canadians are interested in learning more about AMR, with 81 per cent of respondents wanting more government information on the topic.2
Results illustrated that many Canadians shared widespread misconceptions relating to AMR. Of those surveyed, 60 per cent of respondents nationwide believed 'antibiotic resistance' means that a person with an infection is resistant to antibiotics.2
"Antimicrobial resistance occurs when bacteria or other microorganisms develop resistance to antibiotics and other antimicrobial drugs," says Dr. David Patrick, University of British Columbia's School of Population and Public Health. "Antibiotic resistance does not refer to a body's resistance to antibiotics, but to the bacteria's response to antibiotics."
The survey also revealed misunderstandings about whether AMR is something Canadians should be worried about. Nationwide, 44 per cent of respondents believed AMR to be more of a concern in developing countries.
"Antimicrobial resistance affects everyone, everywhere, and that includes Canada, where it is an increasingly serious concern," says Dr. Andrew Morris, Sinai Health System and University Health Network. "It is truly a global health issue that warrants collective action."
To play a role in effectively combating AMR, Canadians can discuss their infections with health care providers and the appropriateness of receiving antibiotic treatment.
"Ensuring we're using appropriate antibiotics through strong antimicrobial stewardship programs will allow clinicians and physicians to take action on diagnostic test results, which is an important strategy to reduce unnecessary prescribing and for the early detection of drug-resistant infections," says Steve Gundersen, president, BD – Canada.
BD, a global medical technology company, commissioned the study to determine the state of public awareness and understanding of AMR across Canada. The company is also collaborating with several other entities, to mobilize a new broad-based AMR public awareness and coalition-building campaign, under the theme I'm a resistance fighter™. The global Antimicrobial Resistance Fighter campaign highlights the roles and impact of health practitioners, professional associations, government leaders, non-government organizations, health agencies, advocacy groups and patients in combating AMR. It focuses on communicating the stories and impacts of organizations and clinicians that are combating AMR, and the testimony of patients and their families who have personally battled antimicrobial resistant infections. Canadians interested in sharing their story or joining this campaign can visit: antimicrobialresistancefighters.org.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to better diagnose disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.
Sources:
- World Health Organization. World Antibiotic Awareness Week, 12-18 November 2018. Last accessed September 24, 2018. http://www.who.int/campaigns/world-antibiotic-awareness-week/en/.
- Leger. Antimicrobial Resistance Awareness Report. 2018.
- O'Neill, J. (2016). Tackling drug-resistant infections globally: Final report and recommendations. The Review on Antimicrobial Resistance, Creative Commons Attribution 4.0 International Public License.
- World Health Organization. Antimicrobial resistance: global report on surveillance 2014. Last accessed September 19, 2018. http://www.who.int/drugresistance/documents/surveillancereport/en/.
SOURCE BD - Canada
New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with type 2 diabetes and established cardiovascular disease
Survival estimates from the EMPA-REG OUTCOME® trial data demonstrate potential long-term benefit of empagliflozin on life expectancy of adults with type 2 diabetes and cardiovascular disease1
BURLINGTON, ON and TORONTO, Nov. 6, 2018 /CNW/ - The journal Circulation published novel results based on data from the landmark EMPA-REG OUTCOME® trial, which suggest that treatment with empagliflozin positively impacts life expectancy in adults with type 2 diabetes and established cardiovascular disease. Using actuarial methods*, and assuming that the demonstrated beneficial effects of empagliflozin remain consistent with long-term use, empagliflozin was estimated to extend life expectancy by 1 to 4.5 years on average, depending on age, when compared with placebo.2
In an analysis of data from 7,020 patients included in the EMPA-REG OUTCOME® trial, estimated life expectancy increased across all ages when adults were treated with empagliflozin as compared to those treated with placebo. Specifically, estimated mean survival in people aged 45 years was 32.1 years with empagliflozin versus 27.6 years with placebo, resulting in a mean survival difference of 4.5 years. In people aged 50, 60, 70 and 80 years old, the mean survival difference with empagliflozin compared to placebo was an additional 3.1 years, 2.5 years, 2 years and 1 year, respectively.3
"Studies show that people with diabetes develop heart disease up to 15 years earlier and have more heart failure than individuals without diabetes. This results in a substantial reduction of life expectancy in patients with diabetes especially when they have heart disease," says Dr. David Fitchett, cardiologist at St Michael's Hospital in Toronto, and a coauthor of the Circulation paper. "Our research indicates empagliflozin can prevent an early death in patients with diabetes, extending life expectancy by as much as 4.5 years."
The primary EMPA-REG OUTCOME® trial results, published in the New England Journal of Medicine in September 2015, demonstrated a 38 percent relative risk reduction in cardiovascular death and a 32 percent relative risk reduction in all-cause mortality with empagliflozin in people with type 2 diabetes and established cardiovascular disease, compared with placebo, over a period of 3.1 years.4 Modelling based on the EMPA-REG OUTCOME® trial data was used to quantify the potential benefit of empagliflozin on residual life span.
"For people with type 2 diabetes and a history of heart disease, this analysis illustrates the benefit of treating with medication that not only lowers glucose but reduces cardiovascular risk," says Dr. Jan Hux, President and CEO of Diabetes Canada. "Diabetes contributes to 30 per cent of strokes and 40 per cent of heart attacks in this country, which is why Diabetes Canada has updated its guidelines in recent years to reflect the importance of identifying and managing cardiovascular risk."
| *Actuarial methods refer to the statistical techniques and analysis used to prepare mortality and other analytical tables |
About Diabetes and Cardiovascular Disease
Canada has the second highest rate of type 2 diabetes in the developed world,5 with over 3.5 million Canadians currently living with the disease, and another seven million at risk of diagnosis.6 Type 2 diabetes is the most common form of diabetes, responsible for around 90 percent of diabetes.7
Due to the complications associated with diabetes, such as high blood sugar, high blood pressure and obesity, cardiovascular disease is a major complication and the leading cause of death associated with diabetes.8, 9, 10 Research from the recent My Heart Matters survey reveals that, although most Canadians with type 2 diabetes (93 per cent) feel they are knowledgeable about their disease management, one in two are unaware their diabetes alone significantly increases the risk of heart attack, heart failure and stroke.11, 12
Having a history of diabetes at age 60 can shorten a person's life span by as much as six years compared with someone without diabetes. And having both diabetes and a history of heart attack or stroke at age 60 can shorten a person's life span by as much as 12 years compared with someone without these conditions.13
Diabetes Canada recommends the use of agents that have been proven to reduce the risk of cardiovascular events for patients with type 2 diabetes and established cardiovascular disease (such as empagliflozin).14
About the EMPA-REG OUTCOME® trial 15
The EMPA-REG OUTCOME® trial was a long-term, multicentre, randomized, double-blind, placebo-controlled trial of more than 7,000 people from 42 countries with type 2 diabetes at high risk for cardiovascular events.
The trial assessed the effect of empagliflozin (10 mg or 25 mg once daily) added to standard of care compared with placebo added to standard of care. Standard of care was comprised of glucose-lowering agents and cardiovascular drugs (including for blood pressure and cholesterol). The primary endpoint was defined as time to first occurrence of cardiovascular death, non-fatal heart attack or non-fatal stroke.
The overall safety profile of empagliflozin was consistent with that of previous trials.
About Empagliflozin
Empagliflozin is an oral, once daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death risk reduction data in the label in several countries.16, 17, 18
Inhibition of SGLT2 with empagliflozin in people with type 2 diabetes and high blood sugar levels leads to excretion of excess sugar in the urine. In addition, initiation of empagliflozin increases excretion of salt from the body and reduces the fluid load of the body's blood vessel system (i.e. intravascular volume). Empagliflozin induces changes to the sugar, salt and water metabolism in the body that may contribute to the reductions in cardiovascular death observed in the EMPA-REG OUTCOME® trial.
Empagliflozin is not approved for people with type 1 diabetes.
About Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in diabetes that centres on compounds representing several of the largest diabetes treatment classes. The alliance leverages the strengths of two of the world's leading pharmaceutical companies. By joining forces, the companies demonstrate commitment in the care of people with diabetes and stand together to focus on patient needs. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributed to the alliance. For more information about the Alliance visit www.boehringer-ingelheim.ca or www.lilly.ca.
About Boehringer Ingelheim (Canada) Ltd.
Improving the health and quality of life of patients is the goal of Boehringer Ingelheim, a research-driven pharmaceutical company. In doing so, the focus is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients' lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the top 20 companies in the pharmaceutical industry. Some 50,000 employees create value through innovation daily for the three business areas: human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. Research and development expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 600 people across Canada.
More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.ca or in our annual report: http://annualreport.boehringer-ingelheim.com.
About Eli Lilly Canada
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by Colonel Eli Lilly, who was committed to creating high quality medicines that meet people's needs, and today we remain true to that mission in all our work. Lilly employees work to discover and bring life-changing medicines to people who need them, improve the understanding and management of disease, and contribute to our communities through philanthropy and volunteerism.
Eli Lilly Canada was established in 1938, the result of a research collaboration with scientists at the University of Toronto which eventually produced the world's first commercially-available insulin. Our work focuses on oncology, diabetes, autoimmunity, neurodegeneration, and pain. To learn more about Lilly Canada, please visit us at www.lilly.ca.
| ___________________________ |
| 1 Claggett B, et al. Long-Term Benefit of Empagliflozin on Life Expectancy in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease. Circulation. 2018;138:1599-1601 |
| 2 Claggett B, et al. Long-Term Benefit of Empagliflozin on Life Expectancy in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease. Circulation. 2018;138:1599-1601 |
| 3 Claggett B, et al. Long-Term Benefit of Empagliflozin on Life Expectancy in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease. Circulation. 2018;138:1599-1601 |
| 4 Zinman B. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117-2128. |
| 5 Canadian Institute for Health Information. International Comparisons: A Focus on Diabetes. November 4, 2015. |
| 6 Diabetes Canada. "Diabetes in Canada". Backgrounder, March 2018. Available at: https://www.diabetes.ca/getmedia/6960f8d5-0869-4233-8ac2-6c669dae7c59/2018-Backgrounder-Canada_KH_AB_KB-edited-13-March-2018_2.pdf.aspx |
| 7 Diabetes Canada. "Types of Diabetes". Diabetes, 2018. Available at: https://www.diabetes.ca/about-diabetes/types-of-diabetes |
| 8 Diabetes Canada. "Complications". Diabetes and You, 2018. Available at: https://www.diabetes.ca/diabetes-and-you/complications/heart-disease-stroke |
| 9 Nwaneri C, Cooper H, Bowen-Jones D. Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis. The British Journal of Diabetes & Vascular Disease. 2013;13(4):192–207. |
| 10 Morrish NJ, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44 Suppl 2:S14–21. |
| 11 Environics Research Group. "My Heart Matters Survey": Online survey conducted among 1,500 Canadians over 18 years of age was completed online between April 13 and May 4, 2018. Slide 5. Table S9 (row 293) in 2018. |
| 12 Environics Research Group. "My Heart Matters Survey": Online survey conducted among 1,500 Canadians over 18 years of age was completed online between April 13 and May 4, 2018. Slide 11. |
| 13 The Emerging Risk Factors Collaboration. Association of Cardiometabolic Multimorbidity With Mortality. JAMA. 2015;314(1):52-60. |
| 14 Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018;42(Suppl 1):S1-S325. |
| 15 Zinman B. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117-2128. |
| 16 Jardiance Product Monograph. Boehringer Ingelheim (Canada) Ltd. April 16, 2018. Last accessed August 2018. |
| 17 European Summary of Product Characteristics Jardiance®, approved May 2018. Data on file. |
| 18 Jardiance® (empagliflozin) tablets U.S. Prescribing Information. Available at: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf |
SOURCE Boehringer Ingelheim (Canada) Ltd.
 |
ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer's Disease
Narrated white paper reveals lessons learned from 15 years of drug development; pressing need to selectively target the toxic oligomer
TORONTO and CAMBRIDGE, MA, Nov. 6, 2018 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today issued a narrated scientific white paper titled: "The critical importance of selectivity when developing antibody therapies for Alzheimer's disease." The white paper highlights the lessons learned from more than 15 years of drug development for Alzheimer's disease (AD) and why selectively targeting its root cause, now understood to be the toxic oligomer, is the most promising therapeutic approach. The presentation is available on the company's website at https://bit.ly/2zpPtpq
In this presentation, Dr. James Kupiec, ProMIS Chief Medical Officer, discusses why selectively targeting toxic oligomers (known as pathologic, misfolded proteins) is critical when developing medicines for neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and ALS (amyotrophic lateral sclerosis). Dr. Kupiec outlines why PMN310, ProMIS' next-generation antibody, has the potential to become a best-in-class therapy among antibody treatments for AD. The paper also discusses design considerations for ProMIS' first clinical trial with PMN310, highlighting the use of novel biomarkers to capture potential early signs of efficacy of PMN310.
"Over the last dozen years, scientists across the Alzheimer's disease research community have come to recognize that it is the toxic oligomer form of amyloid beta (Aβ), and not the other forms such as Aβ monomers and plaque, that initiates the process of brain cell death in Alzheimer's, ultimately leading to the symptoms associated with this devastating disease", commented Dr. Kupiec. "Recent scientific data indicate that a best-in-class antibody therapeutic for Alzheimer's disease should target toxic oligomers without binding to non-toxic forms of Aβ."
Results of preclinical evaluations clearly indicate PMN310 strongly and preferentially binds the toxic oligomers from humans with Alzheimer's disease, and it is therefore highly selective. Contrary to current antibody candidates in development, PMN310 as designed does not bind to Aβ monomers nor plaques or vascular deposits of amyloid.
"Owing to its highly selective binding to toxic oligomers, we do not anticipate observing a dose-limiting side effect such as brain swelling; and because of its unique selectivity, therapeutic doses would not be wasted on superfluous targets. Accordingly, we hope to demonstrate a greater clinical benefit than other Aβ-directed antibodies currently showing encouraging results in clinical trials", stated Dr. Kupiec.
Potential partners and members of the Alzheimer's disease community can access both the narrated white paper and a written transcript directly on the ProMIS Neurosciences website or at https://bit.ly/2zpPtpq
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform -ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
For further information about ProMIS Neurosciences, please consult the Company's website at: www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE ProMIS Neurosciences Inc.
rock-it promotions adds Dr. Martens to its roster
TORONTO, ON — rock-it promotions, named one of Canada’s fastest growing companies by Growth 500 three years in a row, today announced
Dr. Martens as their latest client win. Following a competitive review, the agency will manage all public relations activity in Canada for the global footwear brand.
As agency of record, rock-it promotions will spearhead Dr. Martens' overall PR strategy within Canada, conduct national media relations, manage and execute events, facilitate influencer engagement and celebrity gifting, and manage brand partnerships.
“We’re very excited to partner with this globally recognized and respected footwear brand,” said Debra Goldblatt-Sadowski, President and Founder of rock-it promotions. “We could not be more proud to work alongside a brand designed for people who possess a proud sense of self-expression and we look forward to sharing Dr. Martens exciting new collections and upcoming campaigns.”
“We’re thrilled to return to Canada in a larger PR capacity and focus efforts on the Canadian market,” said Sara LaHaie, US Brand Marketing and PR Manager, Dr. Martens. “We look forward to partnering with rock-it promotions, who demonstrated a strong understanding of the authenticity and diversity of the Dr. Martens brand, as well as the media and influencer landscape in this market.”
About rock-it promotions
Recognized as one of Canada’s leading lifestyle public relations firms, rock-it promotions is a full-service PR agency specializing in media relations, event planning, social media, launch events, press tours, sponsorship and partnerships and much more. The firm specializes in working with brands in a wide variety of industries including fashion, beauty, entertainment, food & beverage, hospitality, and travel & tourism. Current clients include adidas, GUESS, The JUNO Awards, L’Oréal Paris, Casper, Club Med, Toronto Fashion Week and Yorkville Village to name a few. Additionally, rock-it promotions operates two complementary divisions: Fourth Floor Management, a social influencer management arm that represents more than 20 of Canada’s most renowned and respected creative minds of the influencer community; and Tastemakers, a product placement company that pioneered the gifting suite concept in Canada and has been running its coveted lounge for the past 14 years, now called Suite on the Sixth.
About Dr. Martens
The first pair of Dr. Martens boots rolled off the production line on April 1, 1960. With its trademark yellow stitch, grooved sole and heel-loop, it was a boot for workers, initially worn by postmen and policemen; comfortable, durable and lightweight in comparison to its competitors at the time. Throughout Dr. Martens history, the brand has been adopted and subverted by diverse individuals, musicians, youth cultures and tribes. These are the people who stand out from the crowd and their journey of self-expression has always been accompanied by a pair of DM’s. The simple silhouette allows people to customize each pair; whilst on a utilitarian level their famous durability and comfort make them ideal footwear for the world of gigs and street fashion. On an emotional level, they are a flag of attitude and empowerment. The Northamptonshire factory where it all began still exists to this day, in the village of Wollaston. A specific range of ‘Made In England’ products are manufactured here by a small, close-knit team of people schooled in traditional shoe-making and the unique process that makes Dr. Martens like no other shoe on earth.
Twitter: @rockitpromo @drmartens
Instagram: @rockitpromo @drmartensofficial
Flickr: flickr.com/photos/rockitpromo
Website: www.rockitpromo.com , www.drmartens.com
To stay up-to-date on the latest rock-it news, click here to receive event invites, press releases and more.
|
20th Anniversary of National Aboriginal AIDS Awareness Week
Leading Indigenous Voice Faces Funding Impact on HIV Programs
OTTAWA, Nov. 6, 2018 /CNW/ - The Canadian Aboriginal AIDS Network (CAAN) announces Indigenous leadership and their supporters will celebrate its 20thAnniversary of Aboriginal AIDS Awareness Week on November 29, 2018 in Ottawa, ON with a Parliamentary Breakfast followed by December 1 – 6, 2018events across the country (Vancouver, Edmonton, Peace River, Grande Prairie, Saskatoon, Winnipeg and more) to unite an Indigenous response to HIV and AIDS in a similar theme to World AIDS Day: Health For All – Know Your Status.
- Ottawa November 29 Keynote: Hon. Jane Philpott, Minister of Indigenous Services
- Peace River Correctional Centre event includes an open dialogue on Prison Needle Exchange Program with incarcerated inmates.
- Vancouver event focus on Harm Reduction for Indigenous peoples leaving Federal Institutions in Pacific Region.
- Indigenous peoples are over-represented in the HIV epidemic 2.7 times higher than other Canadians.
This series of events will connect Indigenous organizations, government partners, health care providers, and community leaders as they share lessons learned in order to create community readiness and culturally safe approaches to wholistic testing, care and treatment.
For over 20 years Aboriginal AIDS Awareness Week has provided HIV prevention, treatment and support resources and worked with Indigenous communities to empower them to address infectious diseases. In addition, CAAN's Promising Practices documentaries have received awards and accolades and Comcast has acquired global distribution.
The annual campaign is supported by CAAN's network which spans over 400 individuals and AIDS services partners; along with international alliances in 11 countries.
Aboriginal AIDS Awareness Week 2018 will also act as a platform for CAAN to continue to lobby for an urgent review of the HIV and Hepatitis C Community Action Fund, which has left so many long-standing organizations crippled by reduced funding or no funding. CAAN is experiencing the harsh impact of a 46% funding cut from the Community Action Fund.
"CAAN's severely reduced funding decimates the leading voice of First Nations, Inuit, and Métis peoples living with HIV or AIDS and will have severe consequences on both Indigenous health and reconciliation," states Ken Clement, CEO of Canadian Aboriginal AIDS Network. "We struggle to identify and support the newly funded groups in order to add an Indigenous voice to their work, and with our work we face losing the momentum we've made to eradicate the spread of HIV."
The Canadian Aboriginal AIDS Network and its launch co-hosts, Canadian Global Health All-Parliamentary Caucus HIV TB & Malaria, Interagency Coalition on AIDS and Development (ICAD), and Pauktuutit Inuit Women's Association of Canada invite you to participate in Aboriginal AIDS Awareness Week as it addresses different aspects of HIV prevention in a manner that reflects Indigenous cultures and traditional knowledge, and also the unique social, spiritual, economic and political needs of key populations.
For more information, Schedule of Events or to RSVP, visit: www.aboriginalaidsawareness.com
About CAAN www.caan.ca
The Canadian Aboriginal AIDS Network (CAAN) is a non-profit organization that leads a collective response to protect the wholistic wellness of First Nation, Inuit and Métis peoples impacted by HIV, hepatitis C and related diseases and issues, such as mental health, addictions and aging. Through research and programming, it informs and influences public health policy from an Indigenous worldview and advances self-determination to address health determinants with Indigenous traditions, values and knowledge.
About ICAD www.icad-cisd.com/
About Pauktuutit http://pauktuutit.ca/
National non-profit organization representing all Inuit women in Canada.
SOURCE Canadian Aboriginal AIDS Network (CAAN)
Wanderlust Launches “Passport”: a Global Events Membership for the Mindful Traveler
One-Time Purchase Grants Admission to All 2019 Wanderlust Events plus Member-Only Benefits
Passport Goes on Sale November 23, 2018
New York, NY (November 5, 2018) – Wanderlust, producer of the largest series of yoga lifestyle events in the world, continues the celebration of its 10-year anniversary by announcing the creation of Wanderlust Passport. Passport grants entry to all 2019 Wanderlust events—over 50 events in 20 countries on 5 continents—for one price. As your personal gateway to the outdoor adventures, diverse styles of yoga, restorative meditation, unique musical experiences and more, Passport instantly makes you a part of the global mindful movement, with perks, surprises and delights. For more information, please visit www.wanderlust.com/passport/
“A passport is a symbol of our personal wanderlust, our innate desire to travel and roam,” says Sean Hoess, CEO of Wanderlust. “We’ve always sought to incorporate adventure and local cultural experiences into our events as Wanderlust has spanned the globe, and we are excited to offer these experiences to mindful nomads everywhere at an affordable price.”
What is included in Wanderlust Passport?
- Access to all 2019 Wanderlust events. This includes Wanderlust’s signature 4-day festivals and Wanderlust 108 “mindful triathlons” as well as two brand new event types: 2-day festivals, featuring immersive yoga, fitness and wellness programming and food experiences in urban parks across the US, and Immersions, a 1-day deep dive into expert-led topical workshops.
- 50% off Wellspring. Set in Palm Springs, CA and featuring the world’s leading innovators, teachers and socially-conscious companies, Wellspring is one part Wanderlust festival and one part ideas foundry.
- Dedicated email and phone support to help with all event logistics and details.
- Unlimited activity scheduling at all Wanderlust festivals.
- A premium welcome kit suitable for gifting.
- Access to an invite-only Facebook group.
- Exclusive benefits and surprises.
The Wanderlust Passport will go on sale November 23, 2018—Black Friday—for $595 USD. Prices will rise incrementally throughout the year.
More information about the Wanderlust Passport can be found here: www.wanderlust.com/passport/
More information about all Wanderlust events can be found here: https://wanderlust.com/events/
About Wanderlust:
Wanderlust Holdings, LLC is a global yoga lifestyle company founded in 2009. Our mission is to help you find your true north—to live a healthy and inspired life. Wanderlust’s events encompass Wanderlust Festival, the world’s leading multi-day yoga and music festivals, Wanderlust 108, a one-day “mindful triathlon” taking place in urban parks across the globe, and Wellspring, a first-of-its-kind wellness gathering featuring the world’s leading innovators, teachers and socially-conscious companies. In 2012, Wanderlust opened the first of five Wanderlust yoga studios, culminating in the 2015 opening of Wanderlust Hollywood, a 10,000 square foot center in Los Angeles, CA offering yoga and meditation classes, a world-class organic restaurant, and a full-featured performance venue. In 2018, Wanderlust earned B Corporation Certification, meeting rigorous standards for social and environmental performance, ethics, accountability, and transparency in business.
Become a fan of Wanderlust at
Facebook www.facebook.com/wanderlust
Twitter www.twitter.com/wanderlustfest
Instagram http://instagram.com/wanderlustfest
YouTube http://www.youtube.com/user/WanderlustFestival
